Drug discovery and development for acute heart failure drugs: are expectations too high?
Orion Pharma, Critical Care, P.O. Box 65, Espoo, Finland. Electronic address: piero.pollesello@orionpharma.com.
Piero
P
Pollesello
D000208:Acute Disease; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D055808:Drug Discovery; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D006835:Hydrazones / Q000627:therapeutic use*; D011724:Pyridazines / Q000627:therapeutic use*; D000077464:Simendan; D014508:Urea / Q000031:analogs & derivatives* / Q000627:therapeutic use
D002316:Cardiotonic Agents; D006835:Hydrazones; D011724:Pyridazines; C547293:omecamtiv mecarbil; D000077464:Simendan; D014508:Urea
Acute heart failure; Clinical trials; Drug discovery and development; Levosimendan; Omecamtiv mecarbil